EPIMINDER LIMITED (EPI)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EPI

EPI - EPIMINDER LIMITED

FNArena Sector : NONE
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: -2.1
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.83

02 Mar
2026

-0.020

OPEN

$0.81

-2.35%

HIGH

$0.83

342,428

LOW

$0.79

TARGET
$2.33 180.7% upside
FNARENA'S MARKET CONSENSUS FORECASTS
EPI: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 14.7 - 24.0 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 20242025
EPS Basic xxx-14.7
DPS All xxx0.0
Sales/Revenue xxx0.0 M
Book Value Per Share xxx-17.4
Net Operating Cash Flow xxx-17.0 M
Net Profit Margin xxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20242025
Return on Capital Employed xxx-
Return on Invested Capital xxx-167.36 %
Return on Assets xxx-113.24 %
Return on Equity xxx-
Return on Total Capital xxx-107.34 %
Free Cash Flow ex dividends xxx-17.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20242025
Short-Term Debt xxx8 M
Long Term Debt xxx48 M
Total Debt xxx56 M
Goodwill - Gross xxx-
Cash & Equivalents - Generic xxx9 M
Price To Book Value xxx-

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20242025
Capex xxx0.0 M
Capex % of Sales xxx-
Cost of Goods Sold xxx0 M
Selling, General & Admin. Exp & Other xxx27 M
Research & Development xxx12 M
Investments - Total xxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

02/03/2026

1

Speculative Buy

$2.33

180.72%

Epiminder's inaugural first half results provided no material surprises for Morgans. Since listing the company has secured a favourable Medicare reimbursement ruling and completed the first US Minder implant. Nine tier-1 US centres for DETECT have also been signed.

Execution on enrolment is now the key swing factor for sentiment, the broker adds. No changes are made to FY26-28 forecasts and a Speculative Buy rating is maintained. Target is $2.33.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -24.00 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -17.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

EPI STOCK CHART

FNArena News on EPI

1
FNArena Corporate Results Monitor – 02-03-2026

Mar 02 2026 - Australia
2
Next Week At A Glance – 22-24 Dec 2025

Dec 19 2025 - Weekly Reports
3
Next Week At A Glance – 8-12 Dec 2025

Dec 05 2025 - Weekly Reports